About ArteraAI
Artera.ai focuses on personalizing therapy for prostate cancer through its main product, the ArteraAI Prostate Test, which is a clinical laboratory test developed in-house. This test utilizes advanced multi-modal deep learning techniques to analyze patient data and provide tailored treatment options. Unlike many competitors, Artera.ai's test is not experimental; it is used in actual clinical settings, ensuring reliability and effectiveness. The company serves healthcare providers, hospitals, and individual patients, generating revenue through the sale of their prostate test. Artera.ai aims to enhance the treatment of prostate cancer by offering a more personalized approach, backed by rigorous clinical trials and continuous improvement efforts.
Risks
Increased competition from AI diagnostic companies may erode ArteraAI's market share.
Reliance on H&E histopathology images could be challenged by new diagnostic technologies.
Focus on prostate cancer may limit market potential if competitors diversify.
Differentiation
ArteraAI's platform uses multimodal AI for personalized prostate cancer therapy.
The ArteraAI Prostate Test is the first AI-enabled test in NCCN Guidelines.
ArteraAI collaborates with Movember to advance prostate cancer treatment.
Upsides
ArteraAI secured $20 million funding for international expansion and growth.
Inclusion in NCCN Guidelines boosts ArteraAI's credibility and market acceptance.
Partnership with CorePlus enhances validation of ArteraAI Prostate Test.
Funding
EARLY VC
10/31/2023- Andrew Tan.
- Johnson & Johnson
- Coatue Management
- Walden Catalyst Ventures
- Breyer Capital
- Marc Benioff
- Steve Blank
- Jeff Dean
- Rajiv Khemani
- Koch Disruptive Technologies
- Clarence So
- Dennis Wong
- Prosperity7vc
- Lip-Bu Tan
- The Trium Group
- Andy Jacques
- TheFactory
- Jim Breyer
- Amarjit Gill
- Time Ventures
- EDBI
- Wilson Sonsini
- Michael Driscoll